---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007260"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:04:36.138109+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports Q3 net loss $17.6M, discontinues AB-836 capsid inhibitor, cash runway into Q2 2024

## Summary
- Net loss $17.6M ($0.12/share) vs $24.2M loss Q3 2021; revenue $6.0M (+$2.7M YoY) on Qilu license income.
- Cash, equivalents and investments $190.2M; 2022 net cash burn forecast $90-95M; runway into Q2 2024.
- Discontinued AB-836 (oral capsid inhibitor) due to ALT elevations in healthy volunteer arm of Phase 1 trial.
- AB-729 off-treatment data: HBsAg and HBV DNA suppressed up to 44 weeks post-therapy; no relapses in 9/9 patients.
- On-track to complete IND-enabling studies for AB-161 and AB-101, and nominate pan-coronavirus Mpro candidate by year-end.

## SEC filing metadata
- accession: 0001171843-22-007260
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/f8k_110922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007260
- JSON: https://secwatch.observer/filing/0001171843-22-007260.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007260.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported third quarter ended September 30, 2022 results: revenue $6.0 million, net income $17.6 million, EPS $0.12 per basic and diluted common share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $6.0 million
  - Net income: $17.6 million
  - EPS: $0.12 per basic and diluted common share
  - Result: reported results
  source text: the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024. Revenue Total revenue was $6.0 million for the three months ended September 30, 2022 compared to $3.3 million for the same period in 2021. The increase of $2.7 million was due primarily to $2.3 million of revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.